-
USFDA approves Mylan and Biocon’s Fulphila
biospectrumasia
June 05, 2018
Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy.
-
FDA says there is shortage of Mylan’s Epipen in US
biospectrumasia
May 11, 2018
in
Share
.
Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment
-
Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®
biospace
April 26, 2018
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz®Tablets.
-
Mylan, Biocon to launch Adalimumab Biosimilar in EU
biospectrumasia
April 16, 2018
FKB’s product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018.
-
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It
biospace
April 16, 2018
Canonsburg, Pennsylvania-based Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it.
-
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)
biospace
April 12, 2018
Mylan N.V. today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to Humira® developed by Fujifilm Kyowa Kirin Biologics.
-
Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering
biospace
April 08, 2018
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the pricing of a private offering of $1.5 billion aggregate principal amount of senior notes on March 28, 2018
-
FDA Gives Mylan’s New HIV Drug a Thumbs-Up
biospace
March 29, 2018
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients who weigh at least 40 kilograms.
-
Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin® Injection
biospace
March 21, 2018
Mylan N.V. today announced the U.S. launch of the oncology drug Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials
-
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
biospace
March 05, 2018
Global pharmaceutical company Mylan N.V. today announced that it will launch two new HIV treatments, Symfi Lo™ and Cimduo™